Chinese regulatory authorities agreed to review a request that BeiGene’s Bruton’s tyrosine kinase (BTK) inhibitor zanubrutinib be approved to treat patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) ... Read more